November 24, 2015 – The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals’ dabigatran (Pradaxa) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip replacement surgery. There are an estimated 300,000 total hip replacement surgeries performed in the United States each year. Without preventive anticoagulant treatment, the incidence of DVT ranges from 40 to 60 percent for primary elective hip surgery patients.

A new 3-D computer modeling system may significantly improve a surgeon’s ability to select the best-sized donor heart for children receiving heart transplants, according to research presented at the American Heart Association’s Scientific Sessions 2015.

NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved stent into a beating heart was performed successfully in a 53-year-old male patient presenting with severe 4+ mitral regurgitation (MR).

CIRS ATOM phantoms are a full line of anthropomorphic, cross sectional dosimetry phantoms designed to investigate organ dose, whole body effective dose as well as verification of delivery of therapeutic radiation doses.

ATOM is the only line of dosimetry phantoms to range in sizes from newborn to adult. Six models are available: newborn, 1-year, 5-year and 10-year old pediatric phantoms as well as adult male and female phantoms.

Boston Heart Diagnostics announced the launch of StatinSmart, an at-home saliva laboratory developed test that analyzes the SLCO1B1 (Solute Carrier Organic Anion Transporter 1B1) gene for a variant known to increase an individual's risk for developing statin-induced myopathy.

Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now